Triple Negative Breast Cancer (TNBC)
1 competing product in clinical development for Triple Negative Breast Cancer (TNBC).
Pipeline by Phase
Phase 11
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| BBI-355 + Erlotinib + Futibatinib + BBI-825 | Boundless Bio | Phase 1 | Active | 25 |